Physician profile
James M Lawrence
NPI 1669657896
$10,075.31
in general payments reported to CMS, 2019-2025
31 companies · $1,434 in 2025
The $1,434 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $890 · 2020: $1,042 · 2021: $950 · 2022: $1,439 · 2023: $1,723 · 2024: $2,597 · 2025: $1,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,571 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,570.68 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,121.82 | 2019-2025 | |
| Janssen Biotech, INC. | $1,126.45 | 2020-2025 | Tremfya, Simponi Aria |
| Glaxosmithkline, LLC. | $914.46 | 2019-2025 | Benlysta |
| Pfizer INC. | $823.24 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $702.53 | 2022-2025 | Ofev, Cyltezo |
| Astrazeneca Pharmaceuticals LP | $553.65 | 2021-2025 | Saphnelo |
| Amgen INC. | $543.71 | 2019-2025 | Otezla, Enbrel, Tavneos |
| Aurinia Pharma U.S., INC. | $431.61 | 2021-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $400.87 | 2024-2025 | Purified Cortrophin Gel |
| Ucb, INC. | $376.74 | 2019-2024 | Bimzelx, Cimzia |
| Lilly USA, LLC | $156.38 | 2019-2023 | Taltz, Jardiance |
| Regeneron Healthcare Solutions, INC. | $150.24 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $140.40 | 2024-2025 | Acthar |
| Genzyme Corporation | $118.98 | 2023-2024 | |
| Forte Bio-Pharma LLC | $59.74 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $49.35 | 2019 | |
| Strongbridge US INC. | $45.50 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $43.81 | 2021 | |
| Janssen Pharmaceuticals, INC | $41.32 | 2024 | Spravato |
| Cumberland Pharmaceuticals, INC. | $40.39 | 2022 | |
| Scilex Pharmaceuticals INC. | $40.32 | 2024 | |
| Sanofi-Aventis U.S. LLC | $29.00 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $23.86 | 2024 | Arcalyst |
| Celgene Corporation | $22.16 | 2019 | |
| Gilead Sciences, INC. | $21.58 | 2025 | |
| Sandoz INC. | $21.28 | 2023 | Hyrimoz |
| Axsome Therapeutics, INC. | $17.92 | 2025 | Sunosi |
| Exact Sciences Corporation | $15.47 | 2025 | The Cologuard Plus Collection Kit |
| Sobi, INC | $15.40 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.73 | 2024 | |
| Hikma Pharmaceuticals USA | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.